Market open · Oct 1, 1:20 pm ET · After hours $17.65 +0.27%
Open$17.57
Prev close$17.60
Day range$17.45 – $17.82
Volume13.56M
Market cap$18.06B
P/E (TTM)14.8
Dividend yield0.11%
CDE Stock News
Headlines matching Coeur Mining or the CDE ticker, most recent first.
Tianyu Co., Ltd.: Announcement Regarding the Approval of Its Wholly-Owned Subsidiary's Active Pharmaceutical Ingredient by the CDE ReviewSZSI · 5 Sep 2026
The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.Zhitong Finance · 4 Sep 2026
The product of Guobang Pharma's (605507.SH) subsidiary, glyceryl dicaprylate/dicaprate, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE).Zhitong Finance · 15 Sep 2026
Guobang Pharma: Glyceryl Dicocoate, a product of its wholly-owned subsidiary, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE).Breakings · 15 Sep 2026
A Quick Look at Today's Ratings for Coeur Mining(CDE.US), With a Forecast Between $18 to $26.5Market news · 7 Aug 2026
ATB Cormark Capital Markets Downgrades Coeur Mining(CDE.US) to Hold Rating, Cuts Target Price to $18Market news · 7 Aug 2026
BMO Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $26Market news · 6 Aug 2026
RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $23Market news · 12 Aug 2026
No comments yet — be the first to weigh in on CDE.